Publications by authors named "Pastelli N"
Background: Clinical trials and real-world experience have provided evidence for the clinical benefits of mepolizumab, an anti-IL-5 biologic, in severe asthma. However, limited data exist regarding the impact of mepolizumab on airway remodeling.
Objective: We sought to investigate the effect of mepolizumab on airway structural remodeling in patients treated for severe asthma in routine clinical care.
Article Synopsis
- Lung cancer is a major cause of cancer deaths worldwide, and small cell lung cancer (SCLC) is particularly aggressive and often diagnosed late with no established reliable biomarkers.
- This study focused on the expression of two potential biomarkers, PDL1 and DLL3, in endobronchial samples from 44 SCLC patients, noting that high PDL1 expression correlated with better survival, while most patients showed high DLL3 expression.
- The research suggests that the combined high expression of PDL1 and DLL3 may identify patients more likely to benefit from targeted immunotherapy, offering new avenues for treatment and survival predictions in SCLC.
Article Synopsis
- * A case study of a 34-year-old man with a germline STK11 mutation, lacking typical PJS features, reveals he developed lung adenocarcinoma despite being a non-smoker, highlighting the complexity of cancer genetics.
- * Despite treatment efforts, the patient did not benefit from standard therapies and passed away 18 months after diagnosis, underscoring the need for vigilant monitoring of hereditary cancer syndromes like PJS for earlier cancer detection.
An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece.
Lung Cancer (Auckl)
August 2021
Purpose: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred first-line option for patients with advanced, EGFR-mutant non-small cell lung cancer (NSCLC). Afatinib, a second-generation irreversible EGFR-TKI, has been extensively used in Greece in this setting; however, real-world data regarding molecular epidemiology and financial implications of afatinib use are lacking.
Materials And Methods: This was an observational, non-interventional, multicenter, retrospective cohort study, based on real-world data collected from the medical charts/records of patients treated with afatinib between 15/03/2015 and 25/06/2020 and were recorded on a web-based data capture system.
The name of the co-author of E-PS-07-008 (page S294) was presented as 'S. Despina' instead of 'D. Sgouridi' in the authorship group The name has been corrected in the authorship group shown above.
View Article and Find Full Text PDFIntroduction: Lipoma is a benign mesenchymal tumor originating from adipose tissue cells. In the head and neck, this tumor is not common. The occurrence of lipomas in the parotid gland is extremely rare, ranging between 0.
View Article and Find Full Text PDFBlinatumomab, a bispecific T-cell engager antibody construct targeting CD19, has been shown to improve the outcome in patients with relapsed and/or refractory B-cell acute lymphoblastic leukemia. Treatment with blinatumomab demonstrated significant survival benefit over chemotherapy, supporting its use as a bridge therapy to allogeneic hematopoietic stem cell transplantation. Unfortunately, following initial response, approximately 50% of responding patients eventually relapse.
View Article and Find Full Text PDF